Menu

Investors

Press Release

Akebia Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

February 2, 2018 at 4:30 PM EST

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 2, 2018-- Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), granted nine newly-hired employees options to purchase an aggregate of 53,550 shares of Akebia’s common stock on January 31, 2018, as inducements material to each such employee’s entering into employment with Akebia. The options were granted in accordance with NASDAQ Listing Rule 5635(c)(4).

The options have an exercise price of $14.78 per share, which is equal to the closing price of Akebia’s common stock on the grant date. Each stock option vests over four years, with 25% of the shares vesting on the first anniversary of the grant date and the remaining 75% of shares vesting quarterly thereafter, in each case, subject to the new employee’s continued service with the company. Each stock option has a ten-year term and is subject to the terms and conditions of the company’s 2016 Inducement Award Program and a stock option agreement covering the grant.

About Akebia Therapeutics
Akebia Therapeutics, Inc. is a biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor biology. For more information, please visit our website at www.akebia.com, which does not form a part of this release.

Source: Akebia Therapeutics, Inc.

Akebia Therapeutics
John Garabo, 617-844-6130
Director, Corporate Communications
jgarabo@akebia.com

Print Page
Email Page
Contact IR
Email Alerts
Tear Sheet

Akebia Therapeutics, Inc.
245 First Street, Suite 1400
Cambridge, MA 02142

Driving Directions

+1 617.871.2098  phone
+1 617.871.2099  fax

Contact Us